

Haematologica  
HAEMATOL/2018/201848  
Version 1

Older Adults with AML Treated with Intensive Chemotherapy: “Old”  
Prognostic Algorithms May Not Apply

Richard M Stone and Coleman Lindsley

Disclosures: Stone: Outside the submitted work- Clinical Research Support to my institution from AbbVie, Agios, Arog, Lilly, Novartis Consulting in past 3 years: AbbVie, Actinium, Agios, Amgen, Argenix (DSMB) Arog, Astellas, Celgene (includes steering committee and DSMB), Jazz, MacroGenics, Novartis, Ono, Pfizer, Roche, Sumitomo Pertaining to submitted work- none Lindsley: outside the submitted work: Research support from Jazz Consulting for Medimmune, Jazz (ad board), Takeda, and N-of-one. Pertaining to submitted work- none

Contributions: RS and CL wrote the editorial